News on Cancer Biomarkers
Read the latest news on molecular markers used to guide cancer treatment, assess prognosis, or detect relapse from Precision Oncology News.
Clinicians say they are using blood-based tests for patients who can't be biopsied as a way to get test results sooner, but implementing tests smartly and appropriately remains a challenge.
In head-to-head studies, a next-generation EGFR inhibitor and an ALK inhibitor beat their older counterparts in staving of cancer progression.
The first randomized study to show a PARP inhibitor benefits advanced breast cancer patients is also a sign of the expanding utility of BRCA testing in precision medicine.
The IHC test was used in clinical studies that led to Zykadia's approval last week as a first-line option for metastatic NSCLC patients with ALK rearrangements.
The expanded indication makes it a first-line option for metastatic non-small cell lung cancer patients with ALK rearrangements.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
The Ventana PD-L1 assay was approved as a complementary diagnostic for bladder cancer patients being considered for treatment with the immunotherapy Imfinzi.
Researchers said that laboratories participating in BRAF proficiency testing include most of the required reporting elements "to unambiguously convey molecular results."
The analysis from Quest Diagnostic researchers compared the cost-effectiveness of a seven-gene panel test to BRCA1 and BRCA2 testing alone in improving life expectancy.
At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.